Another study also shows that sitagliptin reduces serum CRP levels via inhibiting the activation of NF-κB in T2DM, partially improving endothelial dysfunction in patients with uncontrolled diabetes and CVD [40]. This evidence concerns the gene CRP and type 2 diabetes mellitus.